Zydus Lifesciences is an Indian integrated pharmaceutical company that discovers, develops and commercialises branded and generic medicines, consumer wellness products, biosimilars and medical devices across more than 81 countries. It reported revenue of ₹27,148.4 crore in FY26. Pharmaceuticals made up 82.6% of FY26 segment revenue, followed by consumer products at 14.6% and medical technologies at 2.9%. North America Formulations is its largest business at 44% of total sales, followed by India Formulations at 25%.[1][2]
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.
Sign in to see the revenue split by business segment - free.
Sign inSign in to see dividends, bonuses and splits - free.
Sign in